Mitomycin C) into the distal tumor-feeding arteriesįollowed by temporary embolization with gel foam to obtainĬomplete stasis in the tumor-feeding vessels. Performed injecting the chemotherapy emulsion (Lipiodol, Selective or super-selective TACE procedure was Pre-treatment tumor criteria are considered for organ The MilanĬriteria were assessed prior to bridging treatment as only Than three lesions or multiple tumor feeding arteries In the radioembolization group, Milan criteria for HCC were met significantly less frequently (20.5% vs. Results: Between groups, patients were comparable with regards to age and gender. Multivariable logistic regression and cox proportional hazard regression models were used to evaluate factors associated with tumor recurrence and post-transplant survival. Methods: We retrospectively analyzed prospectively collected data on 131 consecutive HCC patients who underwent liver transplantation between January 2007 and December 2017 at our liver transplant center (radioembolization n = 44, TACE n = 87). Objective of this study was to compare HCC recurrence after liver transplantation following TACE or radioembolization bridging treatment. Both radioembolization and TACE represent potent treatment strategies.īridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?Ġ Department of General, Visceral and Transplant Surgery, University Hospital Essen, Essen, Germanyġ Department of Diagnostic and Interventionalīackground: In hepatocellular carcinoma (HCC) patients, intraarterial therapies are regularly employed as a bridge to liver transplantation to prevent tumor progression during waiting time. Intraarterial bridging treatment leading to tumor necrosis may not only prevent waitlist drop-out but also facilitate long-term successful liver transplantation in HCC patients. ![]() Increasing model of end-stage liver disease (MELD) score and tumor recurrence were independently associated with increased odds of post-transplant death. Multivariable analysis detected increasing recipient age, male gender, complete tumor necrosis and absence of microvascular invasion being independently associated with decreased odds for HCC recurrence. HCC recurrence and overall survival were similar between the groups. On explant specimen, tumor differentiation, microvascular invasion and tumor necrosis were comparable between the groups. Patients in the radioembolization group required significantly fewer intraarterial treatments (1 vs. Between groups, patients were comparable with regards to age and gender. We retrospectively analyzed prospectively collected data on 131 consecutive HCC patients who underwent liver transplantation between January 2007 and December 2017 at our liver transplant center (radioembolization n = 44, TACE n = 87). In hepatocellular carcinoma (HCC) patients, intraarterial therapies are regularly employed as a bridge to liver transplantation to prevent tumor progression during waiting time. Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign? Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma. Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma Following Yttrium-90 Radioembolization Bridging Treatment.Ĭomparison of outcomes between SBRT, yttrium-90 radioembolization. ![]() Long-Term Outcome After Liver Transplantation for Hepatocellular Carcinoma. Transarterial radioembolization for hepatocellular carcinoma: a review Transarterial radioembolization for hepatocellular carcinoma: a review Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis Radioembolization Is a Safe and Effective Treatment for Hepatocellular. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma Transarterial Radioembolization with Yttrium-90 for the Treatment of. Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular Carcinoma and Transjugular Intrahepatic Portosystemic Shunts Outcomes of Locoregional Tumor Therapy for Patients with Hepatocellular.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |